On IL 181596 to Insight Biopharmaceuticals LTD titled “PROCESS FOR PREPARATION OF MIXTURES OF POLYPEPTIDES USING PURIFIED HYDROBROMIC ACID” publishing for opposition purposes, Teva Pharmaceutical Industries LTD filed an Opposition. However, just before publication, Insight filed a Divisional Application (IL 241702).
Teva requested that the Opposition be suspended, pending Examination of the Divisional application claiming that the claims of the two cases are substantially identical and that Insight agreed to the suspension.
Ms Jacqueline Bracha has given Insight 14 days to agree to concur to the request to suspend the Opposition and to explain why it is an appropriate action to take in this case.
Categories: Israel IP, Israel Patent, Israel Patent Agency, Israel Patent Office, Israel Patent Office Rulings, Israel Related, opposition, oppostion, Patents, pharmaceuticals, pharmaceuticals and Biotechnology, Uncategorized, החלטת ביניים, החלטת רשות הפטנטים, פטנט, פטנטים, קניין רוחני, קנין רוחני